{"id":"mci-9042","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy progression"},{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:16:22.669981","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MCI-9042 binds to transthyretin and stabilizes its native tetrameric structure, preventing dissociation into monomers that would otherwise misfold and aggregate into amyloid fibrils. By inhibiting TTR amyloid fibril formation, the drug aims to slow or halt the progression of transthyretin amyloidosis, a progressive neurodegenerative disease caused by accumulation of amyloid deposits in peripheral nerves and other tissues.","oneSentence":"MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:23.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Transthyretin amyloidosis (ATTR amyloidosis)"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT05730621","phase":"PHASE4","title":"A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2023-01-11","conditions":"Sarpogrelate, Blood Viscosity, Peripheral Arterial Disease","enrollment":68},{"nctId":"NCT05083299","phase":"","title":"Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-01-28","conditions":"Chronic Occlusive Arterial Disease","enrollment":1003},{"nctId":"NCT06424548","phase":"NA","title":"Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis.","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Seoul Hospital","startDate":"2024-05-16","conditions":"Stroke, Atherosclerosis","enrollment":100},{"nctId":"NCT06046196","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-11-18","conditions":"Arterial Occlusive Diseases, Intermittent Claudication","enrollment":148},{"nctId":"NCT01869881","phase":"PHASE4","title":"Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-02-01","conditions":"Diabetic Nephropathy","enrollment":151},{"nctId":"NCT03509922","phase":"PHASE4","title":"A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-11","conditions":"Peripheral Artery Disease, PAD","enrollment":60},{"nctId":"NCT03947528","phase":"PHASE1","title":"Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-03-04","conditions":"Healthy","enrollment":38},{"nctId":"NCT03947489","phase":"PHASE1","title":"Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-03-04","conditions":"Healthy","enrollment":38},{"nctId":"NCT03573622","phase":"PHASE1","title":"A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-05-31","conditions":"Healthy","enrollment":62},{"nctId":"NCT03574285","phase":"PHASE1","title":"A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-05-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT01674686","phase":"PHASE4","title":"The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-08-01","conditions":"Variant Angina","enrollment":200},{"nctId":"NCT02959606","phase":"PHASE4","title":"SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-12","conditions":"Peripheral Arterial Disease","enrollment":272},{"nctId":"NCT02393612","phase":"PHASE3","title":"Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2012-10","conditions":"Peripheral Arterial Disease","enrollment":151},{"nctId":"NCT02607436","phase":"PHASE4","title":"Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-07","conditions":"Coronary Artery Disease","enrollment":40},{"nctId":"NCT00147303","phase":"PHASE3","title":"Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-04","conditions":"Cerebral Infarction","enrollment":46},{"nctId":"NCT02097511","phase":"PHASE1","title":"Sarpogrelate Drug Interaction","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2013-12","conditions":"Hypertension, Peripheral Artery Disease","enrollment":9},{"nctId":"NCT02294643","phase":"PHASE3","title":"Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-04","conditions":"Coronary Artery Disease, Diabetes Mellitus, Renal Insufficiency, Chronic","enrollment":220},{"nctId":"NCT01841086","phase":"PHASE1","title":"Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation","status":"COMPLETED","sponsor":"Korea United Pharm. Inc.","startDate":"2011-09","conditions":"Healthy","enrollment":50},{"nctId":"NCT01548274","phase":"NA","title":"Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2010-10","conditions":"Atherosclerosis","enrollment":20},{"nctId":"NCT01429688","phase":"PHASE1","title":"Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT01421576","phase":"PHASE1","title":"Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT01421563","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2011-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT01165567","phase":"PHASE4","title":"The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Seoul National University Boramae Hospital","startDate":"2009-12","conditions":"Chronic Kidney Disease","enrollment":212},{"nctId":"NCT00129805","phase":"PHASE3","title":"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2001-01","conditions":"Cerebral Infarction","enrollment":1510}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sarpogrelate(INN)","ANPLAG(R)"],"phase":"phase_3","status":"active","brandName":"MCI-9042","genericName":"MCI-9042","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein. Used for Transthyretin amyloidosis (ATTR amyloidosis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}